Sangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.18 Per Share

Share on StockTwits

Equities research analysts predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce ($0.18) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.10). Sangamo Therapeutics reported earnings per share of ($0.15) in the same quarter last year, which would indicate a negative year over year growth rate of 20%. The company is expected to issue its next quarterly earnings results on Thursday, February 28th.

On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.68) per share for the current year, with EPS estimates ranging from ($0.88) to ($0.42). For the next financial year, analysts forecast that the firm will report earnings of ($0.89) per share, with EPS estimates ranging from ($1.18) to ($0.44). Zacks’ EPS averages are a mean average based on a survey of research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The business had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. During the same period last year, the business earned ($0.15) EPS. The company’s revenue was up 99.5% compared to the same quarter last year.

SGMO has been the topic of a number of recent analyst reports. ValuEngine cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. Wedbush restated a “hold” rating and issued a $9.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, July 24th. Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. Guggenheim cut shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price target on the stock. in a report on Friday. Finally, BidaskClub cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.00.

In related news, Director H Stewart Parker acquired 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was purchased at an average cost of $13.52 per share, with a total value of $27,040.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $15.39, for a total transaction of $76,950.00. Following the transaction, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $188,527.50. The disclosure for this sale can be found here. Insiders sold a total of 30,000 shares of company stock valued at $432,350 over the last ninety days. 1.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in Sangamo Therapeutics by 3.0% during the 3rd quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock worth $141,063,000 after buying an additional 239,190 shares during the last quarter. Wasatch Advisors Inc. raised its position in Sangamo Therapeutics by 12.0% during the 3rd quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock worth $77,031,000 after buying an additional 486,429 shares during the last quarter. Credit Suisse AG raised its position in Sangamo Therapeutics by 23.5% during the 3rd quarter. Credit Suisse AG now owns 2,184,505 shares of the biopharmaceutical company’s stock worth $37,027,000 after buying an additional 415,764 shares during the last quarter. Northern Trust Corp raised its position in Sangamo Therapeutics by 21.0% during the 2nd quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock worth $18,286,000 after buying an additional 223,870 shares during the last quarter. Finally, Nexthera Capital LP raised its position in Sangamo Therapeutics by 35.7% during the 2nd quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock worth $15,150,000 after buying an additional 280,538 shares during the last quarter. 63.97% of the stock is owned by institutional investors.

Shares of NASDAQ:SGMO traded up $0.80 during trading on Tuesday, reaching $10.80. The stock had a trading volume of 2,212,403 shares, compared to its average volume of 2,249,844. Sangamo Therapeutics has a one year low of $9.81 and a one year high of $27.50. The stock has a market capitalization of $1.13 billion, a P/E ratio of -15.43 and a beta of 3.21. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.32 and a current ratio of 6.32.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Read More: Bull Market

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply